Conversion Disorder
17
2
2
10
Key Insights
Highlights
Success Rate
91% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
5.9%
1 terminated out of 17 trials
90.9%
+4.4% vs benchmark
12%
2 trials in Phase 3/4
20%
2 of 10 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 10 completed trials
Clinical Trials (17)
Metabolic Anomolies Associated With the 6 Month Clinical Evolution of Patients Suffering From Motor Conversion Disorder
Contribution of Inflammation and Neuronal Integrity Markers in Patients With First-episode Conversive Motor Disorder
Observational Study on "Functional Overlay" in Patients With Movement Disorders
Brain-computer Interface Rehabilitation And Virtual Environments in Functional Neurological Disorder (BRAVE-FND)
Efficacy of Dorso-lateral Prefrontal Cortex Stimulation by tDCS in Motor Conversion Disorder Patients
Ketogenic Diet Effects on the Frequency of Non Epileptic Seizures
Embodied Virtual Reality Therapy for Functional Neurological Symptom/ Conversion Disorder
Neuroimaging Biomarkers of Prognosis in Motor Functional Neurological Disorders
Metacognitive Therapy and Neuro-physiotherapy as a Treatment for Functional Movement Disorders
Neuroimaging Biomarker for Seizures
Comparing Different Treatments in Reducing Dissociative Seizure Occurrence
Feasibility Study of Physiotherapy for Functional Motor Symptoms
TMS and Attentional Bias in Functional Motor Disorder
Treatments for Psychogenic Nonepileptic Seizures (NES)
Treatment Trial for Psychogenic Nonepileptic Seizures
Rehabilitation of Conversion Gait Disorder
Cytokine Levels in Conversion Disorder